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Trogocytosis is the transfer of plasma membrane fragments and the molecules they contain between one donor and
one acceptor/acquirer cell. Through trogocytosis, acceptor cells temporarily display and use cell-surface molecules they
do not express themselves, but borrow from other cells. Here, we investigated whether liquid tumors possessed a
trogocytic capability, if immune escape molecules could be acquired by tumor cells, transferred between cells of
the same tumor, and if this could benefit the tumor as a whole.
For this, we investigated trogocytosis in hematological cell lines and freshly isolated hematological tumor cells. We
demonstrate that hematological tumor lines possess a trogocytic capability that allows them to capture membranes
that contain the immune-inhibitory molecule HLA-G from allogeneic as well as from autologous sources. We further
show that freshly isolated hematological tumor cells also possess these capabilities. This work reports for the first time
the trogocytic capabilities of liquid tumor cells and introduces the notion of immune escape strategy sharing among
tumor cells through trogocytosis of membrane-bound immune-inhibitory molecules.
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HLA-G is a tolerogenic molecule which expression was
originally observed and characterized on throphoblasts.
Even though it has recently been suggested that it par-
ticipates in the induction of trophoblast cell fusion
[1,2], HLA-G is best known for its ability to confer pro-
tection to the semi-allogeneic fetus from the maternal
immune system [3,4]. HLA-G differs from classical
MHC class I molecules by its genetic diversity, expres-
sion, structure, and functions. It is characterized by a
relatively low allelic polymorphism and a highly re-
stricted tissue distribution. HLA-G constitutive expres-
sion is mainly restricted to trophoblast cells [3], and to
adult thymic medulla [5], pancreatic islets [6], and stem
cells [7,8]. However, HLA-G can be neo-expressed in
pathological conditions such as transplantation [9],* Correspondence: Joel.LeMaoult@cea.fr
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unless otherwise stated.inflammatory and autoimmune diseases [10], viral in-
fections [11], and cancers [12]. HLA-G expression is
under the control of epigenetic mechanisms. In most
adult tissues, HLA-G gene expression in repressed by
methylation, which can be reversed by demethylating
agents such as 5-aza-2′-deoxycytidine [13]. Of note:
such demethylating agents are used in cancer therapy;
they might therefore have the adverse effect of inducing
immune escape through HLA-G expression. Concern-
ing HLA-G expression regulation, it is under the con-
trol of polymorphism and microenvironmental factors
such as hypoxia and cytokines, and miRNA such as
MiR148a and MiR152 (for review, see [14,15]).
HLA-G is exclusively immune-inhibitory. Under its
membrane-bound and soluble forms, it is able to inhibit
NK cells and cytotoxic T lymphocyte cytolytic activity
[4,16-19], proliferative T cell responses, T cell and NK cell
ongoing proliferation [20-22], and dendritic cell matur-
ation [23,24]. Recent studies have also shown that HLA-G
is capable of inducing the differentiation of regulatory T
cells and antigen-presenting cells (APCs), which can then
inhibit immune responses themselves [20,23,25-27].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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man cancers including melanoma, renal cell carcinoma,
breast carcinoma, and large cell carcinoma of the lung
[12,28-32]. HLA-G expression by tumor cells has been
shown to be important for the escape of immune
surveillance by host T lymphocytes and NK cells
[12,28,29,33-35]. HLA-G promoter specificities even allow
its expression when that of classical HLA-class-I mole-
cules is downregulated. This is particularly evident in
trophoblast cells, but also occurs in tumor cells. Thus,
HLA-G expression by malignant cells may prevent tumor
immune eradication by inhibiting the activity of tumor in-
filtrating NK, cytotoxic T lymphocytes (CTL), and APCs.
The clinical relevance of HLA-G expression by tumors as
a prominent immune escape mechanism was supported
by numerous studies and for both solid and liquid tumors
(for review, see [36,37]). HLA-G is not a tumorigenic
molecule per se, but it could contribute to tumorigen-
esis if expressed by cancer stem cells or precancerous
cells, shielding them from immune destruction during
their evolution processes. Of particular relevance to our
study, HLA-G expression in B cell chronic leukemia
correlated with a strong immunodeficiency and poor
clinical evolution [38,39].
HLA-G acts mainly through two inhibitory receptors:
LILRB1/ILT2 and LILRB2/ILT4 that are differentially
expressed by NK, T, and B cells, and myeloid APCs.
HLA-G was also reported to exert its tumor immune es-
cape functions by the mechanism of trogocytosis [22,40].
Trogocytosis is a mechanism of rapid transfer of mem-
branes and membrane-associated proteins between
interacting cells. Membrane transfers have been ob-
served mainly between immune cells [41], and in par-
ticular for HLA molecules. Although trogocytic transfers
are common and rather easy to observe experimentally,
the mechanisms that underlie them and the molecules
directly responsible for transfer remain unclear. In par-
ticular, trogocytosis was shown to be dependent on
MHC-TCR interactions or costimulatory molecules (for
review, see [42]). Our laboratory described the trogocytic
transfers of HLA-G and its receptor ILT2 [22,40,43]. In
these studies, we could not identify which molecules
were responsible for APC-to-T or tumor-to-NK, or
tumor-to-APC trogocytosis. However, we did demon-
strate that in APC-to-T trogocytosis, multiple molecules
transferred to various degrees. Among these, MHC mol-
ecules and CD86 transferred the most, a finding that is
compatible with the transfer of membrane-bound orga-
nized molecular clusters such as immune synapses or
lipid rafts [40,44]. After trogocytic acquisition, the trans-
ferred molecules retain their original function and it is
now well established that trogocytosis of the HLA-G
molecule can impact the outcome of an immune reac-
tion by conferring protection to the HLA-G acceptorcell, and by conferring sensitivity to inhibition by HLA-G
through the transfer of its receptor ILT2 [22,40,43,45,46].
Most of these studies have been performed using immune
cells as membrane acceptor cells (T cells, B cells, mono-
cytes), and tumor cell lines as membrane-donor cells
[22,40,46,47]. In two studies [22,48], we showed that the
NK cell line NKL was able to efficiently acquire HLA-G1-
containing membranes from an allogeneic HLA-G1-ex-
pressing melanoma line through trogocytosis [22]. These
experiments demonstrated that hematological tumor cells
may also be trogocytic, although it cannot be assumed
that tumor-to-tumor transfers occur by the same mecha-
nisms as APC-to-T cell or tumor-to-effector transfers.
Other reports showed that trogocytosis occurred between
autologous cells [43,46-48]. Taken together, these data
suggest that tumor cells may exchange membranes and
proteins by trogocytosis among each other.
In the present report, we demonstrate in vitro and
ex vivo that tumor cell lines of immune origin, and tumor
cells from malignant hemopathies such as lymphoma or
leukemia malignancies, possess trogocytic capabilities:
they can acquire membranes and the membrane-bound
immune escape molecule HLA-G1 from their surround-
ings and from each other.
Materials and methods
Cells and cell lines
Blood was obtained from patients after informed con-
sent according to the Declaration of Helsinki under
protocol approved by the Institutional Review Board of
the St Louis Hospital, Paris, and participants provided
their written informed consent to participate in this
study. Samples were processed and treated anonymously.
The cell lines used in this study were of monocytic ori-
gin: histiocytic lymphoma (monocyte) U937 cells, acute
monocytic leukemia THP-1 cells, HL-60, and promyelo-
monocytic leukemia KG-1 cells; B cell origin: lympho-
blastoid LCL721.221 cells, Burkitt’s lymphoma Raji cells,
Burkitt’s lymphoma Ramos cells, myeloma RPMI8226
cells, and myeloma U266 cells; T cell origin: acute T cell
leukemia Jurkat cells; and NK cell origin: NK leukemia
NKL cells. LCL721.221 cells transfected with the HLA-
G1 cDNA (LCL-HLA-G1) have been described [49] and
were used as “donor” cells in allogeneic trogocytosis as-
says. Similarly, transfected KG-1 cells (KG1-HLA-G1),
U937 cells (U937-HLA-G1), and THP-1 cells (THP-1-
HLA-G1) were used as membrane “donor cells” in au-
tologous trogocytic assays. NKL cells were maintained in
medium supplemented with 10 IU/ml of IL-2 (Sigma),
whereas U937, THP-1, HL-60, KG-1, LCL, Ramos, Raji,
RPMI8226, U266, and Jurkat cell lines were not. Culture
medium was RPMI 1640 (Invitrogen) supplemented with
2 mML-glutamine, 1 μg/ml of gentamicin and fungizone
(Sigma), and 10% of heat-inactivated FCS (Invitrogen).
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PC5-conjugated anti-CD19 and anti-CD5 were from
Miltenyi; PE-conjugated anti-HLA-G1 MEM-G/9 was
obtained from Exbio, Praha; and PE-conjugated anti-
CD3 was from Beckman Coulter. Biotin-coupled anti-
CD4 and PC5-conjugated anti-biotin antibody were from
Miltenyi. Purified PC5- and PE-conjugated isotype con-
trols were from Miltenyi. For flow-cytometry analyses,
Fc receptors were blocked by a 30-min incubation with
1 μg/μl of pooled purified isotype antibodies in PBS1x.
All staining steps were performed on ice or at less than
4°C and isotype-matched control antibodies were sys-
tematically used. Flow-cytometry analyses were per-
formed on a Canto II cytometer (Beckton Dickinson)
using FlowJo software (Tree Star).
Trogocytosis assays
Trogocytosis assays between allogeneic tumor cells
Thirty-minute co-incubations were set-up between “ac-
ceptor cells” (cell lines or ex vivo B-CLL, B lymphoma,
and T lymphoma cells) and LCL-HLA-G1 “donor” cells
whose membranes had been pre-labeled with the lipo-
philic dye PKH67 (Sigma) following the manufacturer’s
recommendations. We used a 1:1 donor-acceptor ratio, a
total concentration of 106 to 107 cells/ml, and incubation
at 37°C in a 5% CO2-humidified incubator. At the end of
the co-incubation, the cells were placed on ice and all
further steps were performed at less than 4°C. Acquisi-
tion of donor cell-derived membrane and HLA-G1 by
acceptor cells was investigated by flow cytometry.
Trogocytosis assays between cells from the same tumor cell
line
To evidence trogocytosis capabilities in autologous con-
ditions, tumor line cells were split into PKH67-labeled
“donor” cells and PKH67-negative “acceptor” cells, and
then co-incubated back together for 30 min at a 1:1
donor-acceptor ratio (total concentration of 106 to 107
cells/ml), and at 37°C in a 5% CO2 humidified incubator.
The transfer of donor PKH67-labeled membranes onto
“acceptor” trogocytic cells was analyzed by flow cytome-
try. To evidence trogocytic transfer of HLA-G between
autologous tumor lines, HLA-G1-transfected cells were
labeled with PKH67, and then incubated with their non-
transfected counterparts in the same conditions as
above. Acquisition of donor cell-derived membrane and
HLA-G1 by acceptor cells was investigated by flow
cytometry.
Trogocytosis assays between autologous PBMCs from
patients with hematological tumors
Prior to trogocytosis assay, PBMCs were split. One half
of the cells (“acceptor” cells) was labeled with PC5-
conjugated anti-CD5 antibody (B-CLL patients), or CD4(T cell lymphoma) (Miltenyi) and the other half (“donor”
cells) was labeled with PKH67 (Sigma). Both pre-labeled
cell populations were then co-incubated back together
for 30 min at a 1:1 donor-acceptor ratio (total concen-
tration of 106 to 107 cells/ml), and at 37°C in a 5% CO2-
humidified incubator. The acquisition of PKH67-labeled
membranes from donor cells by antibody pre-labeled ac-
ceptor cells was then analyzed by flow cytometry.
Results
Trogocytic capabilities of tumor cell lines in vitro
We performed experiments aimed at demonstrating that
tumor cell lines were trogocytic and capable of acquiring
membranes and the membrane-bound molecule HLA-G
from other cells, be they allogeneic or autologous. In
these experiments, all membrane acceptor cells were
HLA-G-negative, and all membrane-donor cells had
been pre-labeled with the membrane dye PKH67. For
allogeneic trogocytosis experiments, membrane-donor
cells were LCL-HLA-G1 cells since previous work had
demonstrated that they constituted good membrane and
HLA-G1 donor cells [40,46]. For autologous trogocytosis
experiments, membrane-donor cells were cells from the
same cultures as the acceptor cells, which had been pre-
labeled with PKH67, or, when available, PKH67-labeled
HLA-G1-transfected counterparts of the HLA-G1-
negative acceptor cells. After the 30-min co-incubations
of donor and acceptor cells, the transfers of membrane
and HLA-G1 onto the acceptor cells were evaluated by
flow cytometry using PKH67-associated and anti-HLA-
G antibody-associated fluorescence. As an illustration,
the results obtained for the U937 cell line are shown in
Figure 1. As can be seen, on the left for allogeneic trogo-
cytosis experiments and on the right for autologous tro-
gocytic experiments, donor cells (LCL-HLA-G1 and
U937-HLA-G1, respectively) were double-positive for
PKH67-associated fluorescence and membrane-bound
HLA-G1 (PKH67hiHLA-G1hi donor cells). Prior to tro-
gocytosis experiments, acceptor U937 cells were PKH67
and HLA-G1 double-negative. At the end of the experi-
ments, donor cells were still-identified as PKH67hiHLA-
G1hi cells and were gated out. Figure 1 shows that after
allogeneic trogocytosis assay, 87.3% of the originally
PKH67- and HLA-G1-negative acceptor U937 cells dis-
played PKH67-associated fluorescence, and 100% dis-
played HLA-G1-associated fluorescence. Similarly, after
autologous trogocytosis assay, 78.9% of the originally
PKH67- and HLA-G1-negative acceptor U937 cells now
display PKH67-associated fluorescence, and 100% dis-
play HLA-G1-associated fluorescence. These results in-
dicate that U937 acceptor cells have the capability to
acquire membranes and membrane-bound HLA-G1
from allogeneic LCL-HLA-G1 cells and also from au-
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Figure 1 Trogocytic capabilities of tumor cell lines in vitro. As a representative example, trogocytosis capability results obtained for the U937
cell line are presented. Acceptor cells were U937 cells. Membrane-donor cells were LCL-HLA-G1 cells for allogeneic trogocytosis experiments, and
U937-HLA-G1 for autologous trogocytosis experiments. Membrane-donor cells were labeled with the lipophilic dye PKH67 prior to trogocytosis
assay. For both allogeneic and autologous trogocytosis experiments, membrane donor and membrane acceptor cells are shown prior to and at
the end of the 30-min trogocytosis assay. After the trogocytosis assay, PKH67hi donor cells were gated out and trogocytic PKH67low cells and
HLA-G1low cells can be seen. Results shown are representative of three independent experiments.
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Table 1. They show that all cell lines studied were trogo-
cytic, but differed in the extent of their capability to ac-
quire membranes and membrane-associated molecules
from allogeneic and autologous cells. Indeed, the pro-
portion of acceptor cells that had acquired membranes
and/or membrane-bound HLA-G from LCL-HLA-G1cells ranged from 14% (NKL cells) to 99.8% (U937 cells)
in allogeneic conditions, and from 35% (KG-1 cells) to
100% (U937 cells) in autologous conditions. The fact
that these cell lines were trogocytic in both conditions
may indicate that the mechanisms that underlie trogocy-
tosis transfers might not differ between allogeneic and au-
tologous situations. No obvious lineage-related differences
Table 1 Trogocytic capabilities of tumor cell lines in vitro
Allogeneic trogocytic capability Autologous trogocytic capability Autologous (n)








Monocytic U937 62.9 99.8 41.6 100.0 3 3
THP-1 18.2 36.7 36 3.7 3 3
HL-60 23.3 30.8 53.2 n/a 3 3
KG1 22.5 50.4 35.5 36.5 3 3
B cells Ramos 73.5 77.9 37.1 n/a 3 2
Raji 19.8 25.6 54.2 n/a 3 3
RPMI 8226 25.5 23.8 84.8 n/a 3 3
U266 20.2 30.1 75.2 n/a 3 3
T cells Jurkat 16.4 35.9 35.6 n/a 3 3
NK cells NKL 14.2 37.9 47.9 n/a 3 3
The capabilities of tumor cell lines to acquire membranes and membrane-associated HLA-G were investigated using PKH67-labeled allogeneic (LCL-HLA-G1) and
PKH67-labeled autologous cells. For each experiment type, acceptor cells, donor cells, and the mean percentage of acceptor cells that acquired membranes
(PKH67) and/or HLA-G1 from donor cells is shown. The number of independent experiments performed for each line is shown. n/a not applicable for lack of
HLA-G-positive autologous lines.
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in their trogocytic capabilities. U937 and Ramos cells were
the most trogocytic among the myeloid and B cell line-
ages, respectively. The differences between trogocytic cap-
abilities of cell lines of the same lineage might be due to
long-term cell culture, and also to the tumor’s differenti-
ation stage. Finally, HLA-G1 transfer could systematically
be observed. Overall, except for the U937 and Ramos cell
lines which displayed consistent high trogocytic capabil-
ities, the inter-experimental variability was significant
(Additional file 1: Table S1), owing to factors that are obvi-
ously related to cell culture. Because the mechanism of
trogocytosis between tumor cells is not known, we could
not identify these factors.
Trogocytic capabilities of tumor cells from hematological
malignancies
We next investigated if the previous results obtained
in vitro using tumor cell lines held true for human tu-
mors in vivo. Because B cells and B cell lines were
shown to have a high trogocytic capability [50], we fo-
cused primarily on B cell tumors, but 2 T cell lymph-
omas were also included. Because bona fide in vivo
evaluation of membrane exchanges between cells of the
same liquid tumor is not possible, we performed ex vivo
experiments, keeping to an absolute minimum the ex-
perimental time and cell manipulation (see experimental
procedures): experiments lasted less than 2 h altogether
from the time of blood collection to the end of the tro-
gocytosis assays.
As for cell lines above, we evaluated the trogocytic
capability of hematological tumor cells to acquire mem-
branes and membrane-bound HLA-G1 from allogeneic
LCL-HLA-G1 cells, and to exchange membranes amongeach other in an autologous fashion. The autologous
exchange of membrane-bound HLA-G1 between cells
of the same tumor could not be investigated for lack of
HLA-G expression at the surface of the tumors we
obtained.
For allogeneic trogocytosis experiments, membrane-
donor cells were PKH67-labeled LCL-HLA-G1 cells and
acceptor cells were either CD19+ (B-CLL and B cell
lymphomas) or CD3ˉCD4+ (T cell lymphomas) PKH-
negative tumor cells.
As an illustration, the results obtained for cells from
one representative B-CLL patient (patient B-CLL 15)
are shown in Figure 2. As can be seen, on the left for
allogeneic trogocytosis experiments and on the right
for autologous trogocytic experiments, donor cells
(CD19ˉ LCL-HLA-G1 and CD19+-gated B-CLL tumor
cells, respectively) were positive for PKH67-associated
fluorescence and, in the case of LCL-HLA-G1 cells, for
membrane-bound HLA-G1 as well (PKH67hi donor
cells). Acceptor cells in allogeneic trogocytosis experi-
ment were CD19+ B-CLL tumor cells and were negative
for PKH67-associated fluorescence and HLA-G1. In au-
tologous trogocytosis experiments, in order to distinguish
donor and acceptor cells, acceptor cells were pre-labeled
with CD5 prior to their use. In our displays, CD5 specific-
ally marks acceptor cells even though donor and acceptor
cells express it because this molecule does not transfer
from cell to cell by trogocytosis (Additional file 2: Figure
S1). At the end of the experiments, donor cells were still
identified as PKH67hi cells and were gated out, non-
trogocytic acceptor cells were still PKH67-negative,
whereas trogocytic cells were characterized by low PKH67
levels. As can be observed for allogeneic trogocytosis,

























































Figure 2 Trogocytosis capabilities of freshly isolated hematological tumor cells ex vivo. As a representative example, trogocytosis
capability results obtained for tumor cells from the patient B-CLL 15 are presented. In allogeneic trogocytosis assays, donor cells were PKH67-
prelabeled LCL-HLA-G1 cells and acceptor cells were CD19+ B-CLL cells. In autologous trogocytosis assays, donor and acceptor cells were from
the same blood sample; donor cells were PKH67-prelabeled and acceptor cells were prelabeled with CD5. For both allogeneic and autologous
trogocytosis experiments, membrane donor and membrane acceptor cells are shown prior to and at the end of the 30-min trogocytosis assay.
After the trogocytosis assay, trogocytic, PKH67hi donor cells were gated out, and PKH67low cells and HLA-G1low acceptor B-CLL cells can be seen.
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associated fluorescence, and 9.3% display HLA-G1-
associated fluorescence, indicating that B-CLL tumor
cells are trogocytic and can acquire membranes and
membrane-bound HLA-G1 from allogeneic cells. In au-
tologous trogocytosis, 22.2% of the originally PKH67-
and HLA-G1-negative CD19+-gated acceptor B-CLL
cells displayed PKH67-associated fluorescence, demon-
strating that B-CLL tumor cells can acquire membranes
from autologous cells.
Five such experiments could be performed, three on
B-CLL, one on a B cell lymphoma, and one on T cell
lymphoma. In the latter case, acceptor tumor T cells
were CD3−CD4+ and were distinguished from donor Tcells by CD4 pre-labeling since CD4 does not transfer by
trogocytosis [40]. In all cases, trogocytosis was observed
between donor and acceptor cells from the same tumor,
with transfer extents varying between 8.1% and 55.7% of
the acceptor tumor cell population. The results ob-
tained for each individual tumor are shown in Table 2.
Interestingly, these experiments also showed the very
low trogocytic capabilities of acceptor CD3+CD5+ T
cells in autologous conditions (Additional file 3: Figure
S2). This is similar to what had been demonstrated in
the context of multiple myeloma [51]. Thus, these experi-
ments demonstrate that in the pathological context stud-
ied, trogocytosis essentially occurs between hematopoietic
tumor cells ex vivo.
Table 2 Trogocytosis capabilities of tumor cells from hematological malignancy patients
Allogeneic trogocytosis Autologous trogocytosis
Donor cells Trogocytic cells (%) Donor cells Trogocytic cells (%)
Acceptor cells PKH67 HLA-G1 PKH67
T lymphoma LCL-HLA-G1 57.8 35.5 T lymphoma 55.7
B cell Lymphoma (mantle) 12.6 12.5 B cell lymphoma (mantle) 8.1
B-CLL 15 17.9 9.3 B-CLL 15 23
B-CLL 14 14.7 11.7 B-CLL 14 11.5
B-CLL 13 15 9.1 B-CLL 13 22.2
B-CLL 12 0.8 15.7
B-CLL 11 2.5 19.1
B-CLL 10 nt 23.4
B-CLL 9 nt 30.4
B-CLL 8 nt 16.7
B-CLL 7 nt 29
B-CLL 6 nt 30.1
B-CLL 5 nt 5
B-CLL 4 nt 28.5
B-CLL 3 nt 9.6
B-CLL 2 nt 7.4
B-CLL 1 nt 21
Experiments were performed as described in materials and methods and as exemplified in Figure 2 for patient B-CLL 15. The individual results obtained for each indicated
patient are presented. For both allogeneic and autologous trogocytosis experiments, acceptor and donor cells are indicated. The percentage of trogocytic cells is the
percentage of acceptor cells that acquired PKH67 and/or HLA-G1 from PKH67hi donor cells. nt not tested.
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Trogocytosis, i.e., the capability to acquire membranes
and membrane-associated molecules from a cell by an-
other, has been described for non-tumor immune cells
and shown to impact their immunological functions. In
this work, we investigated whether tumor cells of immune
origin were also trogocytic. Working with hematological
cell lines and freshly isolated hematological tumors, we
demonstrate here that trogocytic function was indeed pre-
served in hematological tumors, that membrane ex-
changes happen in autologous situations, and hence are
likely to occur in vivo.
Our previous studies on trogocytosis between tumor
cell lines and non-tumoral immune cells showed that ef-
fector T and NK cells were capable of acquiring mem-
branes and HLA-G1 protein from HLA-G1-expressing
tumor cell lines, and that trogocytosis or HLA-G1 acqui-
sition was not dependent on HLA-G1. Indeed, blocking
the HLA-G1/ILT2 interaction did not prevent HLA-G1
from being transferred from tumor to immune cells.
Rather, HLA-G1 transferred because it was part of
transferred membrane patches whose trogocytosis was
dependent on other molecules that could not be identi-
fied, even though CD28/CD86 or MHC-TCR interac-
tions were ruled out [40]. Fixation of the donor cell’smembrane using PFA was previously shown to inhibit
HLA-G1 trogocytic transfer from tumor cells to acti-
vated T cells [40], and this was confirmed here for
tumor-to-tumor transfers (Additional file 4: Figure S3).
One of the most striking features of trogocytic trans-
fers is that the acceptor cells may display membrane
proteins that they do not express themselves. This has
been demonstrated for T and NK cells in the context of
HLA-G1 trogocytosis [22,40]. As a consequence, the ac-
quired proteins (e.g., HLA-G1) are displayed on the ac-
ceptor cells for a limited time only. Previous studies
from our laboratory showed that HLA-G1 that had
been acquired by trogocytosis was no longer present at
the cell-surface after 24 h for T and NK acceptor cells,
and 6 h for monocytes [22,40,47]. Experiments per-
formed in the context of the present study confirmed
that the life time of acquired HLA-G at the surface of
acceptor tumor cells is limited, and of the order of 24 h
(data not shown).
We previously reported that HLA-G does not direct
its own transfer, and seems to transfer passively from
cell to cell. This relates to the fact that many proteins
are transferred during trogocytosis, including costimula-
tory molecules such as CD86 or CD54, receptors such
as ILT2, and MHC class I and class II molecules [40].
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that most of them also transfer passively. This does not
mean that any molecule can transfer by trogocytosis. In-
deed, we reported that ILT3 or CD4, CD8, CD14, CD19,
and here CD5 are not concerned by trogocytosis, which
suggests that trogocytic exchanges are not random pro-
cesses, but regulated ones.
This begs the question of what the molecules that me-
diate trogocytic transfers are. Previous work has focused
on trogocytosis between antigen-presenting cells and T
cells, or between target cells and cytotoxic T or NK cells.
In most of these cases, trogocytic transfers were associ-
ated with antigen-specificity (T cells) or function (i.e.,
target recognition, NK cells) [22,52]. However, previous
studies show that trogocytic transfers are only partially
dependent on antigen-specificity: for instance, in case of
antigen-specific interaction between non-activated donor
and acceptor T cells, the TCR is involved in the transfer
process, but when T lymphocytes are activated, trogocy-
tosis occurs independently of TCR engagement, and
with a higher efficiency [40]. In another study, we dem-
onstrated trogocytosis between autologous cells in the
absence of foreign antigen [43], and in the present re-
port, we show that B and monocytic tumor cell lines are
capable of trogocytosis in autologous conditions and in
the absence of antigen, strengthening the notion that
trogocytosis is at least partially independent of antigen-
specificity. Nonetheless, the molecules that are respon-
sible for trogocytosis remain elusive.
B-CLL progressively lost their trogocytic capability
upon culture, sometimes as fast as in 24 h (data not
shown). This indicates that the trogocytic capability of
tumor cells is highly dependent on microenvironmental
factors, which means that the levels of trogocytosis
might be higher in vivo than what we observed ex vivo.
As stated above, we do not know which molecules may be
responsible for tumor-to-tumor membrane exchanges. It
is therefore difficult to predict which microenvironment
factors may modulate the expression and/or function of
these molecules and, down the line, the extent of trogocy-
tic exchanges. Keeping B-CLL in culture medium supple-
mented with autologous serum rather than FCS allowed
B-CLL cells to retain their trogocytic capabilities longer
(not shown). Thus, microenvironmental factors support-
ing trogocytic capability might be cytokines, growth fac-
tors, stress factors, and more generally molecules present
within the serum, rather than nutrient deprivation or mi-
croenvironmental conditions such as hypoxia for instance.
Trogocytic exchanges between tumor cells in vivo are
relevant because we demonstrated that the transferred
proteins might be functional in their new cell hosts.
This is even more likely if donor and acceptor cells are
cells of the same tumor. We already demonstrated in vitro
that trogocytosis could contribute to tumor escape. Indeed,HLA-G1 acquisition by T cells from HLA-G1-expressing
tumor cells rendered them temporarily suppressive. Re-
cently, this hypothesis was strengthened by Brown et al.
[51], who confirmed our previous in vitro results and dem-
onstrated in an all-autologous ex vivo system that T cells
can acquire HLA-G from autologous multiple myeloma
tumor cells, turning them into regulatory cells. Here, we
also show that T cells can acquire membranes from autolo-
gous B-CLL ex vivo, and confirm that such transfers re-
main rare events. However, our results, obtained with the
same blood samples, show that in B-CLL, tumor-to-tumor
membrane exchanges are prominent. The meanings of
such exchanges remain to be explored in depth, but already
the interest for the tumor of transferring HLA-G between
its constituent cells can be envisioned. For instance, it is
known that some but not all B leukemia cells and multiple
myeloma cells from the same tumor can express HLA-G
[38,53-56], which is capable of protecting them from NK
cell cytolysis, and thus constitutes an immune escape
mechanism [57]. Therefore, by transferring HLA-G and
possibly other immune-inhibitory molecules, tumor cells
may share some of their immune escape strategies, as our
in vitro model showed here. For a tumor whose cellular
constituents heterogeneously express immune escape mol-
ecules such as HLA-G, trogocytic sharing presents definite
advantages, such as (i) conferring extra-protection to those
cells which do not express the transferred protein, and (ii)
diversifying the array of immune escape strategies that
each cell uses. This would strengthen the overall resistance
of the whole tumor to anti-tumoral immunity. This also
means that blocking trogocytosis might constitute a new
way to restore anti-tumor immunity, and emphasizes the
need to precisely characterize the molecular mechanisms
that are involved in trogocytic exchanges.Additional files
Additional file 1: Table S1. Inter-experimental variability for trogocytic
capabilities of tumor cell lines in vitro. Standard deviation values (STD)
obtained for the data presented in Table I.
Additional file 2: Figure S1. CD5 does not transfer to acceptor cells by
trogocytosis. The representative results obtained for patient number B-CLL 15
are shown. Freshly isolated PBMC from B-CLL patients were split and labeled
or not with anti-CD5, generating donor and acceptor cell populations,
respectively. Donor and acceptor cells were then used in a trogocytosis
assay and the transfer of CD5 from the CD5hi donor cells to acceptor
CD19+ cells was investigated by flow cytometry. No transfer of CD5 was
observed in any patient, and after trogocytosis assay, CD5+ and CD5-
populations were still clearly distinguishable.
Additional file 3: Figure S2. Low trogocytic capabilities of CD3+ T cells
from B-CLL patients. Autologous trogocytosis experiments were performed
as detailed in the text and PKH67 acquisition by CD5-prelabelled acceptor
CD3+ T cells was studied. Representative results obtained for patient B-CLL
15 are shown. PKH acquisition by acceptor B-CLL cells (22%) and by CD3+ T
cells (3.5%) are shown.
Additional file 4: Figure S3. Fixation of donor cells with PFA prevents
trogocytosis. Representative results obtained for one B-CLL patient are
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described in Materials and Methods, except that donor cells were either
fixed with 0.5% paraformaldehyde in PBS1x (PFA) or not prior to the
trogocytosis assay. The transfer of PKH67-labeled membranes onto
acceptor cells was investigated by flow cytometry. No trogocytic
transfer was observed when fixed donor cells were used.Competing interests
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